ClinicalTrials.gg
RecruitingNCT06151652Updated Feb 1, 2024

Effect of Alpha-Lipoic Acid Supplementation on the Incidence of Postoperative Atrial Fibrillation in Cardiac Surgery Patients

A Phase 4 interventional study of Alpha Lipoic Acid 600 MG Oral Tablet and Placebo in Postoperative Atrial Fibrillation, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Ain Shams University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jan 2023, registered Sep 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrial Fibrillation by Ain Shams University — 3 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Ain Shams University.

Started
2023
the only one that year
Phase 4
2 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Atrial Fibrillation by Ain Shams University, this one is the only one that started in 2023, is one of 2 in phase 4, and was the 7th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 11 studies in Atrial Fibrillation by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrial Fibrillation by Ain Shams University, or all of them as a file.
02

Study summary

ALA is administered orally since it is without difficulty absorbed in the stomach. ALA goes through the blood brain barrier and does not show toxic effects and actions at doses used for prophylactic and therapeutic purposes. This has encouraged us to use an efficient anti-oxidant and anti-inflammatory agent, alpha-lipoic acid (biochemical) as a relevant option to prevent POAF.

Read the detailed description

Investigators computed on the basis of findings from a prior study found the incidence of POAF after cardiac surgery of about 25% . Assuming a slightly lower alpha-lipoic acid' effect to previous study. If the true relative risk of AF for experimental subjects relative to controls is 0.5 , with α equivalent to 0.5 and power (1 - β) is 0.8, the estimated sample size is 152 experimental subjects and 152 control subjects in order to be able to reject the null hypothesis that this relative risk equals 1 with probability (power) of 0.8. investigators used the uncorrected chi-squared statistics to evaluate this null hypothesis. STATA software version and taking into account a possible dropout of 15%, the total sample size was: 304 + 0.15 (304) × 2 = 350 subjects of which there will be 175 controls and 175 experimental subjects %, assuming an enrolment ratio of 1:1.

03

Conditions studied

  • Postoperative Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I
  • Male or female patients above 18 years of age who are scheduled for cardiac surgery.

Exclusion criteria

Exclusion Criteria:

  • Any urgent or emergency surgery.
  • Poor Left ejection volume (EF \< 30%).
  • Intake of or any antiarrhythmic drugs except beta blockers during the last month before surgery
  • Unable or unwilling to provide informed written consent.
  • Pregnancy or lactation
  • Known to the study drug.
  • Current treatment with antioxidants or alpha-lipoic acid for any indication.
  • Infection or inflammatory disease except coronary artery disease.
  • Left atrium size >70 mm.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
350 participants (estimated)

Study arms

  • Placebo comparator
    Group 1 (Control group, N = 175 patients)

    which will include patients adopted to the hospital standard of care.

    Drug: Placebo

  • Active comparator
    Group 2 (Test group, N = 175 patients)

    which will include patients who will receive Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.

    Drug: Alpha Lipoic Acid 600 MG Oral Tablet

Interventions

  • DrugThioctic AcidStudies of Thioctic AcidThioctic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. • Number of Participants with POAF

    Time frame: 1 month

Secondary outcomes

  1. Total intensive care unit length-of-stay

    number of days at intensive care unit

    Time frame: 3 months

  2. Total hospital length-of-stay

    number of days at hospital

    Time frame: 3 months

  3. 30 days mortality

    deaths number

    Time frame: 1-month

  4. Serum creatinine

    creatinine level

    Time frame: 5 days

  5. Major adverse cardiovascular outcomes

    (Myocardial injury - Stroke - Permanent pacemaker - Pericardial effusion and pleural effusion- Bleeding)

    Time frame: 1 month

  6. Duration of ventilation

    hours needed to remove ventilator

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Mar 2024, 14 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 14 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2023
First posted
Nov 30, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Mar 1, 2024
CompletionEst.
Apr 1, 2024
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06151652
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Jan 1, 2023
Primary completion
Mar 1, 2024 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Feb 1, 2024

Study contacts

noha tarek mohammed, MSC
Contact
noha.tarek20@pharma.asu.edu.eg
00201007541786
Marwa Adel, PhD
Contact
Marwa Adel, PhD
study director · Ain Shams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thioctic Acid

Start the discussion